[1]
|
Oeing, C.U., Tschöpe, C. and Pieske, B. (2016) The New Esc Guidelines for Acute and Chronic Heart Failure 2016. Herz, 41, 655-663. https://doi.org/10.1007/s00059-016-4496-3
|
[2]
|
魏安华, 李娟. 《中国心力衰竭诊断和治疗指南2018》药物更新透视[J]. 医药导报, 2019, 38(5): 539-543.
|
[3]
|
Bui, A.L., Horwich, T.B. and Fonarow, G.C. (2011) Epidemiology and Risk Profile of Heart Failure. Nature Reviews Cardiology, 8, 30-41. https://doi.org/10.1038/nrcardio.2010.165
|
[4]
|
Oikonomou, E., Vogiatzi, G., Tsalamandris, S., et al. (2018) Non-Natriuretic Peptide Biomarkers in Heart Failure with Preserved and Reduced Ejection Fraction. Biomarkers in Medicine, 12, 783-797.
https://doi.org/10.2217/bmm-2017-0376
|
[5]
|
Tominaga, S. (1989) A Putative Protein of a Growth Specific Cdna From Balb/c-3t3 Cells Is Highly Similar to the Extracellular Portion of Mouse Interleukin 1 Receptor. FEBS Letters, 258, 301-304.
https://doi.org/10.1016/0014-5793(89)81679-5
|
[6]
|
Weinberg, E.O., Shimpo, M., De Keulenaer, G.W., et al. (2002) Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. Circulation, 106, 2961-2966.
https://doi.org/10.1161/01.CIR.0000038705.69871.D9
|
[7]
|
Yancy, C.W., Jessup, M., Bozkurt, B., et al. (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136, e137-e161.
|
[8]
|
曾艳, 谭华清, 唐湘宇, 等. 可溶性ST2与心血管疾病关系的研究进展[J]. 实用心脑肺血管病杂志, 2019, 27(5): 112-116.
|
[9]
|
Demyanets, S., Kaun, C., Pentz, R., et al. (2013) Components of the Interleukin-33/ST2 System Are Differentially Expressed and Regulated in Human Cardiac Cells and in Cells of the Cardiac Vasculature. Journal of Molecular and Cellular Cardiology, 60, 16-26. https://doi.org/10.1016/j.yjmcc.2013.03.020
|
[10]
|
Mccarthy, C. and Januzzi, J. (2018) Soluble St2 in Heart Failure. Heart Failure Clinics, 14, 41-48.
https://doi.org/10.1016/j.hfc.2017.08.005
|
[11]
|
Mueller, T., Rehman, S.U. and Januzzi, J.L. (2008) Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients with Acute Heart Failure. Journal of the American College of Cardiology, 52, 1458-1465.
https://doi.org/10.1016/j.jacc.2008.07.042
|
[12]
|
杨东慧. 血浆sST2与不同类型心力衰竭的关系[J]. 中国分子心脏病学杂志, 2017, 17(6): 2321-2324.
|
[13]
|
Shah, R.V., Januzzi, J.L., Picard, M.H., et al. (2009) Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients with Acute Dyspnea. Circulation Heart Failure, 2, 311-319. https://doi.org/10.1161/CIRCHEARTFAILURE.108.833707
|
[14]
|
Liu, H., Sun, R.-R., Li, X.-C., et al. (2014) Biomarkers and Heart Disease. European Review for Medical and Pharmacological Sciences, 18, 2927-2935.
|
[15]
|
王同霞, 陈章荣. 可溶性ST2与心力衰竭患者预后的评价[J]. 心血管病学进展, 2020, 41(5): 495-498.
|
[16]
|
徐亚妹, 葛均波. 新型心衰标志物sST2的生物学特征和临床意义[J]. 中华检验医学杂志, 2015(7): 498-501.
|
[17]
|
Myers, G.L., Christenson, R., et al. (2009) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease. Clinical Chemistry, 55, 84-378.
https://doi.org/10.1373/clinchem.2008.115899
|
[18]
|
Xia, W., Huang, Y., Chen, Y., et al. (2011) Acute Myocardial Ischemia Directly Modulates the Expression of Brain Natriuretic Peptide at the Transcriptional and Translational Levels via Inflammatory Cytokines. European Journal of Pharmacology, 670, 7-12. https://doi.org/10.1016/j.ejphar.2011.09.012
|
[19]
|
陈华, 周懿忆, 戴屹东. NT-proBNP的临床应用进展[J]. 标记免疫分析与临床, 2015, 22(1): 69-72.
|
[20]
|
韩肖肖, 杨蒙, 邵淑梅, 谷秀娟. NT-proBNP在急性冠状动脉综合征中的研究进展[J]. 医学理论与实践, 2018, 31(4): 491-493, 502.
|
[21]
|
李立健, 饶绍奇, 田镭钢, 梁岩. BNP或NT-proBNP对冠心病的临床意义[J]. 海南医学, 2017, 28(5): 784-787.
|
[22]
|
金雅丽, 张倩辉, 郭艺芳. 左心室射血分数保留的心力衰竭研究现状[J]. 心血管病学进展, 2010, 31(1): 96-98.
|
[23]
|
Oktay, A.A., Rich, J.D. and Shah, S.J. (2013) The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 10, 401-410. https://doi.org/10.1007/s11897-013-0155-7
|
[24]
|
Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37, 2129-2200.
|
[25]
|
徐俊波, 黄刚, 蔡琳, 等. 2019ESC-HFA射血分数保留性心力衰竭诊断共识的解读[J]. 心血管病学进展, 2019, 40(9): 1193-1195, 1211.
|
[26]
|
Januzzi, J.L., Morss, A., Tung, R., et al. (2006) Natriuretic Peptide Testing for the Evaluation of Critically Ill Patients with Shock in the Intensive Care Unit: A Prospective Cohort Study. Critical Care, 10, R37.
https://doi.org/10.1186/cc4839
|
[27]
|
Wang, F., Pan, W., Pan, S., et al. (2011) Usefulness of N-Terminal Pro-Brain Natriuretic Peptide and C-Reactive Protein to Predict ICU Mortality in Unselected Medical ICU Patients: A Prospective, Observational Study. Critical Care (London, England), 15, R42. https://doi.org/10.1186/cc10004
|
[28]
|
王云. NT-proBNP在心力衰竭诊断及治疗效果评估中的检测价值[J]. 心血管病防治知识(学术版), 2019, 9(17): 41-42.
|
[29]
|
杨国平. 急性呼吸困难患者检测NT-proBNP的护理体会[J]. 安徽卫生职业技术学院学报, 2014(3): 84-85.
|
[30]
|
闫福堂, 苏宝凤, 詹颉, 等. 血清可溶性ST2与血BNP在心力衰竭患者中的相关性研究[J]. 现代检验医学杂志, 2015, 30(6): 78-79, 83.
|
[31]
|
崔圆, 金凤表, 孙瓅贤, 等. 血清GDF-15、sST2、BNP检测在慢性心力衰竭患者心功能评估中的价值[J]. 山东医药, 2016, 56(17): 1-4.
|